News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
There are 38.4 million people with diabetes in the United States
Approval is based on positive data from the Phase 3 ECHELON-3 trial
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Granules now have a total of 53 ANDA approvals from USFDA
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
Subscribe To Our Newsletter & Stay Updated
